Drug intelligence / Profile preview

Daiad-TRA

Development stage: Preclinical
Lead developer: StradBio
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

Daiad-TRA is a computationally-designed, hyperstable cytokine mimetic being developed by StradBio for the treatment of autoimmune diseases. It is part of the company's proprietary Daiad™ platform, which focuses on creating biologics with enhanced stability and precision. While specific molecular targets for Daiad-TRA have not been publicly disclosed, the platform utilizes 'AND' logic gates to ensure activity is localized to specific physiological environments, potentially reducing systemic toxicity. The drug is currently in the lead optimization stage of preclinical development.

Targets

IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)

Beyond the preview

Go deeper on Daiad-TRA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daiad-TRA.

Explore the full profile